ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Astellas Pharma Global Development Inc., Medical University Of Vienna

Conditions

FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)ependymoma and atypical teratoid rhabdoid tumor (ATRT)rare CNS tumorsrecurrent/progressive medulloblastoma

Phase 1

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

CompletedCTIS2024-512469-15-00

Astellas Pharma Global Development Inc.FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start: 2020-12-08End: 2025-03-17Target: 45Updated: 2025-03-04

Phase 2

MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors

RecruitingCTIS2024-515626-92-00

Medical University Of Viennaependymoma and atypical teratoid rhabdoid tumor (ATRT), rare CNS tumors, recurrent/progressive medulloblastoma

Start: 2013-10-18Target: 100Updated: 2025-11-28